2024
Weekly Bortezomib Decreases Rates of Peripheral Neuropathy without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab
Yi I, Gaspar E, Eighmy W, Roeder H, Bar N. Weekly Bortezomib Decreases Rates of Peripheral Neuropathy without Diminishing Efficacy As Compared to Twice Weekly Bortezomib in Combination with Lenalidomide, Dexamethasone and Daratumumab. Blood 2024, 144: 7004-7004. DOI: 10.1182/blood-2024-199190.Peer-Reviewed Original ResearchTwice-weekly bortezomibTwice-weekly groupTwice-weekly dosingWeekly bortezomibMultiple myelomaPeripheral neuropathyBortezomib doseTwice-weeklyFrontline treatmentRate of PNDay 1Rates of peripheral neuropathyMedian follow-up timeTreatment efficacyBortezomib-induced peripheral neuropathyResponse rateWeeks groupBortezomib dose reductionBortezomib-containing regimensBortezomib-induced PNDose of bortezomibDiagnosis of MMIncidence of PNSingle-center studyFollow-up timeP-377 Impact of Weekly Versus Twice Weekly Bortezomib on Rates of Peripheral Neuropathy in Combination With Lenalidomide, Dexamethasone and Daratumumab
Yi I, Gaspar E, Eighmy W, Roeder H, Bar N. P-377 Impact of Weekly Versus Twice Weekly Bortezomib on Rates of Peripheral Neuropathy in Combination With Lenalidomide, Dexamethasone and Daratumumab. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s251. DOI: 10.1016/s2152-2650(24)02279-1.Peer-Reviewed Original Research
2020
Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma
Patel K, Parker T, Di M, Bar N, Huntington S, Giri S. Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma. Blood 2020, 136: 51-52. DOI: 10.1182/blood-2020-141972.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioQuality-adjusted life yearsBest supportive careRefractory multiple myelomaMultiple myelomaSupportive careProbabilistic sensitivity analysesDisease progressionIncremental effectivenessIncremental costPost-progression therapyTwice-weekly bortezomibLarge randomized trialsProgression-free survivalUS payer perspectiveIncremental lifetime costOne-way sensitivity analysesCost-effectiveness ratioQuality of lifeCost of treatmentCost-effectiveness analysisVD progressionAnnual discount rateAdverse eventsHazard ratio